Beverly A Mock

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8368146/publications.pdf

Version: 2024-02-01

82	3,728	186265	133252
papers	citations	28 h-index	59 g-index

85	85	85	5340
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nature Genetics, 2004, 36, 1133-1137.	21.4	1,034
2	The nature and identification of quantitative trait loci: a community's view. Nature Reviews Genetics, 2003, 4, 911-916.	16.3	390
3	Increased Mammalian Lifespan and a Segmental and Tissue-Specific Slowing of Aging after Genetic Reduction of mTOR Expression. Cell Reports, 2013, 4, 913-920.	6.4	278
4	Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex. Nature Communications, 2018, 9, 4229.	12.8	131
5	Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression. ACS Chemical Biology, 2016, 11, 139-148.	3.4	112
6	Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood, 2011, 117, 1228-1238.	1.4	109
7	Genetic regulation of leishmanial and mycobacterial infections: the Lsh / Ity / Bcg gene story continues. Immunology Letters, 1994, 43, 99-107.	2.5	100
8	B Cellâ€“Specific Deficiencies in mTOR Limit Humoral Immune Responses. Journal of Immunology, 2013, 191, 1692-1703.	0.8	85
9	A linkage map of mouse Chromosome 1 using an interspecific cross segregating for the gld autoimmunity mutation. Mammalian Genome, 1992, 2, 158-171.	2.2	83
10	CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell Death and Differentiation, 2011, 18, 1174-1183.	11.2	83
11	Efficiency Alleles of the Pctr1 Modifier Locus for Plasmacytoma Susceptibility. Molecular and Cellular Biology, 2001, 21, 310-318.	2.3	82
12	p16INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB. Oncogene, 2003, 22, 2285-2295.	5.9	74
13	IL9 maps to mouse chromosome 13 and human chromosome 5. Immunogenetics, 1990, 31, 265-270.	2.4	65
14	mTOR intersects antibody-inducing signals from TACI in marginal zone B cells. Nature Communications, 2017, 8, 1462.	12.8	65
15	The Murine Homologue of the Human Interleukin-8 Receptor Type B Maps near the Ity-Lsh-Bcg Disease Resistance Locus. Genomics, 1993, 18, 410-413.	2.9	60
16	The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription. Nature Communications, 2019, 10, 2071.	12.8	60
17	Genetic and Physical Mapping of 2q35 in the Region of the NRAMP and IL8R Genes: Identification of a Polymorphic Repeat in Exon 2 of NRAMP. Genomics, 1994, 24, 295-302.	2.9	59
18	mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood, 2011, 118, 6803-6813.	1.4	48

#	Article	IF	Citations
19	The B-Lymphocyte Maturation Promoting Transcription Factor BLIMP1/PRDI-BF1 Maps to D6S447 on Human Chromosome 6q21â€“q22.1 and the Syntenic Region of Mouse Chromosome 10. Genomics, 1996, 37, 24-28.	2.9	44
20	A Mouse Homeo Box Gene, Hox-1.5, and the Morphological Locus, Hd, Map to Within 1 cM on Chromosome 6. Genetics, 1987, 116, 607-612.	2.9	43
21	Expression of murine cyclin B1 mRNAs and genetic mapping of related genomic sequences. Genomics, 1992, 13, 1018-1030.	2.9	35
22	CHUK, a Conserved Helix-Loop-Helix Ubiquitous Kinase, Maps to Human Chromosome 10 and Mouse Chromosome 19. Genomics, 1995, 27, 348-351.	2.9	32
23	Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility. Blood, 2009, 114, 2952-2960.	1.4	32
24	A brain L-type calcium channel Î±1 subunit gene (CCHL1A2) maps to mouse chromosome 14 and human chromosome 3. Genomics, 1991, 11, 914-919.	2.9	31
25	The Plasmacytoma Resistance Gene, Pctr2, Delays the Onset of Tumorigenesis and Resides in the Telomeric Region of Chromosome 4. Blood, 1997, 90, 4092-4098.	1.4	30
26	Genes on chromosomes 1 and 4 in the mouse are associated with repair of radiation-induced chromatin damage. Genomics, 1988, 2, 257-262.	2.9	29
27	Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14982-14987.	7.1	29
28	Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation. Molecular Cancer Therapeutics, 2017, 16, 2008-2021.	4.1	29
29	Mouse chromosome 4. Mammalian Genome, 1991, 1, S51-S78.	2.2	27
30	Characterization of clinically used oral antiseptics as quadruplex-binding ligands. Nucleic Acids Research, 2018, 46, 2722-2732.	14.5	27
31	TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Molecular Oncology, 2014, 8, 261-272.	4.6	25
32	A Small Molecule Stabilizer of the MYC G4-Quadruplex Induces Endoplasmic Reticulum Stress, Senescence and Pyroptosis in Multiple Myeloma. Cancers, 2020, 12, 2952.	3.7	24
33	T-cell receptor V T? genes in natural populations of mice. Immunogenetics, 1988, 27, 51-56.	2.4	23
34	Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity. Cancer Letters, 2014, 354, 336-347.	7.2	22
35	New strains of inbred SENCAR mice with increased susceptibility to induction of papillomas and squamous cell carcinomas in skin. , 1997, 20, 143-150.		21
36	Mouse Chromosome 4. Mammalian Genome, 1992, 3, S55-S64.	2.2	19

#	Article	IF	Citations
37	Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy. Clinical Cancer Research, 2016, 22, 277-283.	7.0	19
38	Mapping of the Ly-4 (L3T4) T-cell differentiation antigen on mouse chromosome 6 by the use of RFLPs in an interspecific cross. Immunogenetics, 1988, 27, 396-398.	2.4	18
39	Gene organization and chromosome location of the neural-specific RNA binding protein Elavl4. Gene, 1998, 208, 139-145.	2.2	18
40	The gene for Lap18, leukemia-associated phosphoprotein p18 (metablastin), maps to distal mouse Chromosome 4. Mammalian Genome, 1993, 4, 461-462.	2.2	17
41	cFOS-SOX9 Axis Reprograms Bone Marrow-Derived Mesenchymal Stem Cells into Chondroblastic Osteosarcoma. Stem Cell Reports, 2017, 8, 1630-1644.	4.8	17
42	The gene for lysyl oxidase maps to mouse chromosome 18. Genomics, 1992, 14, 822-823.	2.9	16
43	Mml1,a New Common Integration Site in Murine Leukemia Virus-Induced Promonocytic Leukemias Maps to Mouse Chromosome 10. Virology, 1996, 224, 224-234.	2.4	15
44	Fatty acid oxidation is required for embryonic stem cell survival during metabolic stress. EMBO Reports, 2021, 22, e52122.	4.5	14
45	The gene for the dihydropyridine-sensitive calcium channel Î±2 subunit (CCHL2A) maps to the proximal region of mouse chromosome 5. Genomics, 1992, 13, 1325-1327.	2.9	12
46	The gene for the Î±1 subunit of the skeletal muscle dihydropyridine-sensitive calcium channel (Cchl1a3) maps to mouse chromosome 1. Genomics, 1992, 14, 1089-1091.	2.9	12
47	Conventional Co-Housing Modulates Murine Gut Microbiota and Hematopoietic Gene Expression. International Journal of Molecular Sciences, 2020, 21, 6143.	4.1	10
48	Isolation and mapping of four new DNA markers from mouse Chromosome 4. Mammalian Genome, 1992, 3, 653-655.	2.2	9
49	The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility. Journal of Biological Chemistry, 2019, 294, 16756-16764.	3.4	9
50	Mouse chromosome 15. Mammalian Genome, 1991, 1, S241-S268.	2.2	8
51	A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses. Journal of Immunological Methods, 2013, 390, 52-62.	1.4	8
52	The Role of p16INK4a (Cdkn2a) in Mouse Plasma Cell Tumors. Current Topics in Microbiology and Immunology, 1999, 246, 363-368.	1.1	8
53	WDR26 and MTF2 are therapeutic targets in multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 203.	17.0	8
54	Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis. Molecular Cancer Therapeutics, 2020, 19, 2221-2232.	4.1	7

#	Article	IF	Citations
55	The infrapopulation dynamics of trypanosomes in red-spotted newts. Parasitology, 1984, 88, 267-282.	1.5	6
56	Longitudinal Patterns of Trypanosome Infections in Red-Spotted Newts. Journal of Parasitology, 1987, 73, 730.	0.7	6
57	Plasmacytoma-Associated Neuronal Glycoprotein,Pang,Maps to Mouse Chromosome 6 and Human Chromosome 3. Genomics, 1996, 34, 226-228.	2.9	6
58	Mouse chromosome 4. Mammalian Genome, 1998, 8, S68-S90.	2.2	6
59	Mouse Chromosome 15. Mammalian Genome, 1992, 3, S220-S232.	2.2	5
60	Mouse chromosome 15. Mammalian Genome, 1993, 4, S211-S222.	2.2	5
61	The Reign of Antibodies: A Celebration of and Tribute to Michael Potter and His Homogeneous Immunoglobulin Workshops. Journal of Immunology, 2018, 200, 23-26.	0.8	5
62	Attenuation of immuneâ€mediated bone marrow damage in conventionally housed mice. Molecular Carcinogenesis, 2020, 59, 237-245.	2.7	5
63	Mouse Chromosome 4. Mammalian Genome, 1999, 10, 943-943.	2.2	3
64	Structure and Localization of Mouse Pmscl1 and Pmscl2 Genes. Genomics, 2000, 64, 106-110.	2.9	3
65	Mouse chromosome 4. Mammalian Genome, 1997, 7, S60-S79.	2.2	2
66	Mouse tumor susceptibility genes identify drug combinations for multiple myeloma. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.8	2
67	Abstract A73: De-convoluting therapeutic resistance in a pancreatic cancer model: Pharmacogenomic evaluation of intratumoral clonal heterogeneity. , 2015, , .		1
68	Conditional deletion of mTOR discloses its essential role in early Bâ€cell development. Molecular Carcinogenesis, 2022, 61, 408-416.	2.7	1
69	Cover Image, Volume 59, Issue 2. Molecular Carcinogenesis, 2020, 59, i.	2.7	0
70	Abstract LB-74: A high-throughput RNAi sensitization screen of rapamycin identifies targets for rational drug combination strategies. , 2010, , .		0
71	Abstract 805: mTORC protein levels affect class switch recombination, somatic hypermutation, and antibody production. , 2011, , .		0
72	Abstract 4734: Genes cooperatively downregulated by combined mTOR/histone deactylase (HDAC) inhibition are overexpressed in myeloma patients with lower survival. , 2012, , .		0

#	Article	IF	Citations
73	Abstract 4408: A functional genomics approach for identification of sirolimus sensitizer genes regulated by HDAC inhibitors.. , 2013, , .		0
74	Abstract 2217: A systems pharmacogenomic approach to identify synergistic molecular mechanisms of combined mTOR/HDAC inhibition.. , 2013, , .		0
75	Abstract 1555: Use of a mouse model of constitutive mTOR inhibition to identify molecular modulators of acquired resistance.. , 2013, , .		0
76	Abstract 1629: Identification and biological characterization of a novel class of small molecules to inhibit c-myc transcription. , 2014, , .		0
77	Abstract 5472: Systems pharmacogenomics approach identifies synergistic molecular action of combined MTOR/HDAC inhibition on MYC. , 2014, , .		0
78	Abstract 2309: Murine model of dual mTORC kinase inhibition identifies CDK6 as a synergistic target in T-ALL. , 2015, , .		0
79	Abstract B40: Selective suppression of Myc transcription with a G-quadruplex stabilizing small molecule. , 2015, , .		0
80	Abstract 2833: Genetic and pharmacologic inhibition of mTOR delays mortality due to thymc lymphoma formation in mice and is associated with decreases in cell cycle proteins. , 2016, , .		0
81	Abstract 322: Selective inhibition of MYC expression by a small molecule G-quadruplex stabilizer. , 2016, , .		0
82	Abstract 194: Effective targeting of MYC expression with a novel nucleic acid binding (G4-quadruplex) small molecule coupled with HDAC inhibition synergizes to limit myeloma growth. , 2017, , .		0